Systemic Myostatin Inhibition via Liver-Targeted Gene Transfer in Normal and Dystrophic Mice
Open Access
- 11 February 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (2), e9176
- https://doi.org/10.1371/journal.pone.0009176
Abstract
Myostatin inhibition is a promising therapeutic strategy to maintain muscle mass in a variety of disorders, including the muscular dystrophies, cachexia, and sarcopenia. Previously described approaches to blocking myostatin signaling include injection delivery of inhibitory propeptide domain or neutralizing antibodies. Here we describe a unique method of myostatin inhibition utilizing recombinant adeno-associated virus to overexpress a secretable dominant negative myostatin exclusively in the liver of mice. Systemic myostatin inhibition led to increased skeletal muscle mass and strength in control C57 Bl/6 mice and in the dystrophin-deficient mdx model of Duchenne muscular dystrophy. The mdx soleus, a mouse muscle more representative of human fiber type composition, demonstrated the most profound improvement in force production and a shift toward faster myosin-heavy chain isoforms. Unexpectedly, the 11-month-old mdx diaphragm was not rescued by long-term myostatin inhibition. Further, mdx mice treated for 11 months exhibited cardiac hypertrophy and impaired function in an inhibitor dose–dependent manner. Liver-targeted gene transfer of a myostatin inhibitor is a valuable tool for preclinical investigation of myostatin blockade and provides novel insights into the long-term effects and shortcomings of myostatin inhibition on striated muscle.Keywords
This publication has 63 references indexed in Scilit:
- Myostatin inhibits IGF-I-induced myotube hypertrophy through AktAmerican Journal of Physiology-Cell Physiology, 2009
- Adeno-Associated Virus (AAV) Serotype 9 Provides Global Cardiac Gene Transfer Superior to AAV1, AAV6, AAV7, and AAV8 in the Mouse and RatHuman Gene Therapy, 2008
- Relative persistence of AAV serotype 1 vector genomes in dystrophic muscleGenetic Vaccines and Therapy, 2008
- Myostatin Directly Regulates Skeletal Muscle FibrosisPublished by Elsevier BV ,2008
- Dystrophin-deficient cardiomyopathy in mouse: Expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heartNeuromuscular Disorders, 2008
- Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitorsProceedings of the National Academy of Sciences, 2008
- Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liverBlood, 2007
- Myostatin does not regulate cardiac hypertrophy or fibrosisNeuromuscular Disorders, 2007
- Lack of myostatin results in excessive muscle growth but impaired force generationProceedings of the National Academy of Sciences, 2007
- Age-Dependent Effect of Myostatin Blockade on Disease Severity in a Murine Model of Limb-Girdle Muscular DystrophyThe American Journal of Pathology, 2006